EMPA-KIDNEY:恩格列净减少肾脏疾病进展或CV死亡

{"title":"EMPA-KIDNEY:恩格列净减少肾脏疾病进展或CV死亡","authors":"C. de Koning","doi":"10.55788/ce33490e","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":261282,"journal":{"name":"Medicom Conference Report ASN 2022","volume":"53 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death\",\"authors\":\"C. de Koning\",\"doi\":\"10.55788/ce33490e\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":261282,\"journal\":{\"name\":\"Medicom Conference Report ASN 2022\",\"volume\":\"53 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicom Conference Report ASN 2022\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55788/ce33490e\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicom Conference Report ASN 2022","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55788/ce33490e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}